Ascendis Pharma

Ascendis Pharma is a global biopharmaceutical company headquartered in Copenhagen, Denmark, founded in 2007 based on the TransCon technology platform. It is publicly traded on Nasdaq under the ticker ASND following an initial public offering in 2015. The company applies TransCon technology to develop therapies in Endocrinology Rare Disease and Oncology, and collaborates with partners worldwide on TransCon-based products in other therapeutic areas and markets. Its approved products include YUVIWEL, SKYTROFA, and YORVIPATH.

Ascendis Pharma was founded in 2007 based on the innovative TransCon technology platform. It is headquartered in Copenhagen, Denmark and is publicly traded following an initial public offering in 2015 (Nasdaq: ASND). The company has research facilities in Germany and offices across Europe and the United States. It is advancing programs in Endocrinology Rare Disease and Oncology, and collaborates with partners around the world on the development of TransCon-based products in other therapeutic areas and markets.

Guided by core values of Patients, Science, and Passion, applying TransCon technology to develop new therapies with best-in-class potential.

• YUVIWEL

  Achondroplasia treatment using TransCon technology, authorized and available in the United States.

• SKYTROFA

  Growth Hormone Deficiency treatment using TransCon technology, authorized in the United States and European Union & EEA, available in the United States, Austria, and Germany.

• YORVIPATH

  Hypoparathyroidism treatment using TransCon technology, authorized in the United States, European Union, EEA, & UK, available in the United States, Austria, France, Germany, Italy, and Spain.

1. 1Ascendis Pharma: Patients. Science. Passion.ascendispharma.com
2. 2About Us | Ascendis Pharmaascendispharma.com
3. 3Corporate Responsibility | Ascendis Pharmaascendispharma.com
4. 4Our Products | Ascendis Pharmaascendispharma.com
5. 5Ascendis Pharma (Denmark)wikidata.org